Cumberland Pharmaceuticals director Krogulski buys $4516 in stock

Published 12/09/2025, 13:36
Cumberland Pharmaceuticals director Krogulski buys $4516 in stock

Director Kenneth Krogulski of Cumberland Pharmaceuticals Inc (NASDAQ:CPIX), a $51.31 million market cap company that has delivered an impressive 163.85% return over the past year, acquired shares of common stock in a series of transactions between August 1, 2025, and August 29, 2025. The total purchase amounted to $4516, with individual prices ranging from $2.84 to $4.01, below the current trading price of $3.43.

Krogulski purchased a total of 1356 shares of Cumberland Pharmaceuticals common stock. Each transaction involved the purchase of either 68 or 12 shares. The purchases were executed on various dates throughout August: August 1, 4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 25, 26, 27, 28 and 29. According to InvestingPro analysis, the stock is currently trading near its Fair Value, with 8 additional key insights available to subscribers.

Following these transactions, Krogulski directly owns 289717 shares of Cumberland Pharmaceuticals Inc. The purchases were made under a pre-arranged 10b5-1 trading plan adopted on November 14, 2024. Get comprehensive insights into CPIX’s valuation, financial health, and growth potential with the detailed Pro Research Report, available exclusively on InvestingPro.

In other recent news, Cumberland Pharmaceuticals Inc. reported a 10% year-over-year increase in revenue for the second quarter of 2025, totaling $10.8 million. Despite this positive revenue growth, the company’s earnings per share (EPS) did not meet expectations, registering a loss of $0.02. This earnings shortfall has been noted by analysts and contributed to a decline in investor sentiment. The company’s stock has experienced volatility, trading near the lower end of its 52-week range. Analysts from various firms have been closely monitoring these developments. Cumberland Pharmaceuticals’ financial results are a key focus for investors looking to understand the company’s current standing. These recent developments highlight the challenges the company faces amid its revenue growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.